Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedJul 05, 2026
DataAggregated Company Financials
Companies549
  • 7D4.1%
  • 3M12.0%
  • 1Y41.1%
  • YTD14.6%

The Biotech industry is up 4.1% in the last week, with AbbVie up 3.0%. Meanwhile, Evommune actually underperformed within the industry, shrinking 49% in the last week. This takes the industry's 12 month performance to a gain of 41%. Earnings are forecast to grow by 25% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 06 Jul 2026US$1.5tUS$169.9b-US$12,048,903,585.0317.3x-120.5x8.5x
Wed, 03 Jun 2026US$1.3tUS$170.1b-US$12,254,543,832.3915.9x-104.2x7.5x
Fri, 01 May 2026US$1.3tUS$166.4b-US$11,523,557,783.4116.3x-109x7.5x
Sun, 29 Mar 2026US$1.2tUS$166.1b-US$13,456,373,319.7015.1x-91.1x7.4x
Tue, 24 Feb 2026US$1.3tUS$168.1b-US$13,480,534,435.8122.3x-99.3x8x
Thu, 22 Jan 2026US$1.2tUS$163.5b-US$15,109,734,670.4719.7x-81.1x7.5x
Sat, 20 Dec 2025US$1.2tUS$163.6b-US$15,771,044,262.7320.7x-76.3x7.4x
Mon, 17 Nov 2025US$1.2tUS$163.9b-US$16,321,163,359.0117.4x-72.6x7.2x
Wed, 15 Oct 2025US$1.1tUS$163.4b-US$18,202,723,107.4917.1x-62.7x7x
Fri, 12 Sep 2025US$1.1tUS$163.6b-US$18,333,642,586.0515.5x-58.4x6.6x
Sun, 10 Aug 2025US$1.0tUS$163.2b-US$15,518,415,597.7813.7x-65.7x6.3x
Tue, 08 Jul 2025US$960.1bUS$155.8b-US$23,411,059,915.0016.5x-41x6.2x
Thu, 05 Jun 2025US$932.3bUS$155.9b-US$23,955,369,687.0216.6x-38.9x6x
Sat, 03 May 2025US$948.4bUS$153.8b-US$24,594,164,084.6620.9x-38.6x6.2x
Mon, 31 Mar 2025US$816.7bUS$118.6b-US$36,941,707,628.6024.4x-22.1x6.9x
Wed, 26 Feb 2025US$854.7bUS$117.1b-US$37,887,617,142.3517.4x-22.6x7.3x
Fri, 24 Jan 2025US$972.9bUS$149.5b-US$26,306,845,907.1117.4x-37x6.5x
Sun, 22 Dec 2024US$956.2bUS$149.9b-US$26,389,992,070.3815.7x-36.2x6.4x
Tue, 19 Nov 2024US$990.8bUS$150.0b-US$26,801,381,083.8817.2x-37x6.6x
Thu, 17 Oct 2024US$909.2bUS$113.1b-US$36,028,650,557.2521.9x-25.2x8x
Sat, 14 Sep 2024US$913.2bUS$113.2b-US$35,849,665,110.5923.4x-25.5x8.1x
Mon, 12 Aug 2024US$862.3bUS$112.7b-US$36,815,169,721.7821.6x-23.4x7.7x
Wed, 10 Jul 2024US$1.1tUS$164.5b-US$28,071,564,685.9628.5x-40.7x6.9x
Fri, 07 Jun 2024US$1.2tUS$164.6b-US$26,702,448,993.8528x-43.3x7x
Sun, 05 May 2024US$1.1tUS$163.7b-US$26,731,775,868.3424.3x-42x6.9x
Tue, 02 Apr 2024US$1.2tUS$164.5b-US$23,680,262,586.0424.1x-49.8x7.2x
Thu, 29 Feb 2024US$1.2tUS$167.4b-US$21,465,686,557.0613.4x-56.3x7.2x
Sat, 27 Jan 2024US$1.4tUS$204.7b-US$22,646,483,045.0018.3x-63.4x7x
Mon, 25 Dec 2023US$1.4tUS$204.9b-US$22,149,017,627.0019.4x-61.9x6.7x
Wed, 22 Nov 2023US$1.2tUS$204.7b-US$22,046,246,661.0018.1x-55.4x6x
Fri, 20 Oct 2023US$1.2tUS$207.4b-US$13,089,607,875.0016.6x-93.9x5.9x
Sun, 17 Sep 2023US$1.3tUS$207.5b-US$12,865,929,372.0017.5x-99.8x6.2x
Tue, 15 Aug 2023US$1.3tUS$207.7b-US$12,584,014,109.0016.6x-102.4x6.2x
Thu, 13 Jul 2023US$1.1tUS$186.5b-US$15,948,766,717.0013.2x-70.8x6.1x
Price to Earnings Ratio

-70.8x


Total Market Cap: US$1.1tTotal Earnings: -US$15,948,766,717.00Total Revenue: US$186.5bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average -59.2x202420252026
Current Industry PE
  • Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 6.9x is lower than the industry's current PS ratio of 8.5x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 3.0% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.63%
Healthcare2.29%
Biotech4.10%
Biotech4.10%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ABBV AbbVieUS$261.073.0%
+US$13.6b		37.9%PE128.3x
VRTX Vertex PharmaceuticalsUS$528.047.5%
+US$9.3b		14.9%PE30.9x
AMGN AmgenUS$374.154.4%
+US$8.5b		25.5%PE25.9x
MRNA ModernaUS$79.7618.6%
+US$5.0b		161.6%PS14.2x
GILD Gilead SciencesUS$131.272.7%
+US$4.2b		17.5%PE17.7x

Latest News

AMGN
US$374.15
Amgen
7D
4.4%
1Y
25.5%
VRTX
US$528.04
Vertex Pharmaceuticals
7D
7.5%
1Y
14.9%
ABBV
US$261.07
AbbVie
7D
3.0%
1Y
37.9%
ORKA
US$85.21
Oruka Therapeutics
7D
-5.9%
1Y
576.3%
VCYT
US$57.08
Veracyte
7D
-5.6%
1Y
107.5%
Narrative Update • Jul 02

VCYT: Raised Guidance And New Cancer Tests Will Drive Medium Term Story

Veracyte's updated analyst price target has shifted higher from $53.00 to about $67.60, as analysts factor in revised assumptions around profitability, reimbursement stability in its Afirma and Decipher testing assets, and potential contribution from newer platforms such as molecular residual disease and Prosigna. Analyst Commentary Recent research on Veracyte points to a generally constructive tone, with several bullish analysts updating their models and price targets in light of company discussions and revised assumptions around its testing portfolio.
QURE
US$41.81
uniQure
7D
-12.0%
1Y
189.9%
Narrative Update • Jul 02

QURE: FDA Reversal And 2026 BLA Plan Will Drive Huntington’s Outlook

Analysts have lifted the uniQure fair value estimate from about $52.56 to $64.47, citing recent FDA feedback on AMT-130 that, in their view, improves visibility on a potential accelerated approval path and supports higher modeled revenue growth with a lower assumed discount rate and P/E multiple. Analyst Commentary Recent Street research on uniQure has shifted sharply following the latest FDA Type B meeting on AMT-130, with multiple firms revising price targets and ratings after the company outlined plans for a potential accelerated approval filing.
PRAX
US$318.52
Praxis Precision Medicines
7D
-2.8%
1Y
574.0%
MRNA
US$79.76
Moderna
7D
18.6%
1Y
161.6%
REGN
US$654.27
Regeneron Pharmaceuticals
7D
3.4%
1Y
19.5%
EVMN
US$12.96
Evommune
7D
-48.5%
1Y
n/a
ALNY
US$312.78
Alnylam Pharmaceuticals
7D
7.3%
1Y
-5.8%
Narrative Update • Jun 30

ALNY: Cardiomyopathy Expansion And AI Partnerships Will Drive Long Term Upside

Alnylam Pharmaceuticals' analyst-derived fair value estimate has been revised from $491.92 to $434.72 as analysts temper revenue growth and margin assumptions, following mixed adjustments to price targets and updated views on the Amvuttra launch and TTR franchise trajectory. Analyst Commentary Recent commentary on Alnylam Pharmaceuticals shows a mix of optimism around the long term potential of the TTR franchise and more cautious views on execution and valuation in the near term.
GILD
US$131.27
Gilead Sciences
7D
2.7%
1Y
17.5%
TNGX
US$29.46
Tango Therapeutics
7D
-6.4%
1Y
416.8%
NTRA
US$279.32
Natera
7D
6.6%
1Y
72.7%
AUPH
US$15.61
Aurinia Pharmaceuticals
7D
-9.4%
1Y
105.7%
TGTX
US$53.31
TG Therapeutics
7D
-4.5%
1Y
45.2%